Geron to Host a Virtual Investor Event in November
October 15 2021 - 04:05PM
Business Wire
Geron Corporation (Nasdaq: GERN) will host a virtual investor
event on November 9 at 4:00 p.m. ET. Topics to be covered at the
event, include:
- The unmet medical needs in lower risk myelodysplastic syndromes
and refractory myelofibrosis and the disease modification potential
of imetelstat, Geron’s first-in-class telomerase inhibitor.
- Expansion opportunities for imetelstat into new indications and
in combination with other drugs.
- A live physician panel discussion and question-and-answer
session with:
- Dr. Swaminathan Iyer, Professor, Department of
Lymphoma/Myeloma, Division of Cancer Medicine, The University of
Texas MD Anderson Cancer Center, Houston, Texas
- Dr. John Mascarenhas, Associate Professor of Medicine, Icahn
School of Medicine at Mount Sinai, New York, New York
- Prof. Uwe Platzbecker, Director, Clinic and Policlinic for
Hematology, Cell Therapy and Hemostaseology, University Hospital,
Leipzig, Germany
A live webcast of the presentation will be available through the
Investor Relations section of Geron’s website under Events.
Following the presentation, the webcast will be archived and
available for replay for a period of 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused
on the development and potential commercialization of a
first-in-class telomerase inhibitor, imetelstat, in myeloid
hematologic malignancies. The Company currently is conducting two
Phase 3 clinical trials: IMerge in lower risk myelodysplastic
syndromes and IMpactMF in refractory myelofibrosis. For more
information about Geron, visit www.geron.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211015005443/en/
Olivia Bloom Chief Financial Officer investor@geron.com
media@geron.com
Geron (NASDAQ:GERN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Mar 2023 to Mar 2024